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A number of experimental (i.e., animal) models have been developed to induce chronic focal
epilepsy. Three of the most commonly employed are the alumina cream, kainic acid, and the
electrical kindling techniques. A fourth approach involving the application ofminutequantities of
tetanus toxin to discrete brain sites, although relatively under-utilized, may be favorably
compared to the aforementioned models.
INTRODUCTION
It has been estimated that focal epilepsy affects approximately 0.4 percent to 0.5
percent of the population in the United States [1,2] or about one million people [3].
Experimental (i.e., animal) models are essential for a thorough study of the develop-
ment and expression of focal epilepsy, as well as the preclinical evaluation of new
therapeutic approaches. Over the past 45 years, a variety of such models have been
developed. These models may be divided into those which produce an acute epilepto-
genic focus and those which produce a chronic epileptogenic focus. Herein, the terms
"acute" and "chronic" will be used to describe epileptiform syndromes which prevail
for several hours to several days, and several days to several months, respectively.
While the acute models have contributed to our knowledge ofthe convulsive state and
have been instrumental in single-cell studies as well as the investigation ofphenomena
such as status epilepticus, the chronic models are probably more appropriate tools for
the study of naturally occurring epilepsy, which is essentially chronic. Other models
with some characteristics of a chronic nature such as the cobalt [4-6], tungstic acid
[7,8], zinc sulfate [9,10], freezing [11], and blood-brain barrier [12,13] methods are
not discussed here. These models are disadvantageous and not commonly used for the
following reasons: their limited ability to induce chronic epileptogenic foci, their
production of diffuse and/or crater-like lesions, and the great length of time they
require to produce an epileptiform syndrome. The more effective and commonly used
chronic models are those involving alumina cream [14], kainic acid [15], and kindling
[16]. Since a comparative review has not been written in fourteen years [17], we
present here an updated, critical review of the alumina cream, kainic acid, kindling,
and tetanus toxin methods, the latter being a potentially superior but relatively
under-utilized model.
THE ALUMINA MODEL
In 1942, L.M. Kopeloff was the first investigator to produce chronic, focal
epileptogenic lesions in experimental animals [14]. While studying the effects of
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various chemical agents on the pre-central cortex of monkeys and rabbits, Kopeloff
found that the application ofalumina cream resulted in the experimental induction of
spontaneous recurrent seizures [14]. In the past 45 years, the alumina cream technique
has become a widely used experimental model for focal epilepsy, as it creates foci
which remain active for several months [18] to several years [19] and produces
seizures which may increase in frequency until treatment with anticonvulsants
becomes necessary [20]. Table 1 presents the major alumina cream studies conducted
since 1942 [14,21-50]. A number ofpoints deserve further attention. First, while some
techniques produce epileptogenic foci in a wide variety of mammalian, reptilian, and
amphibian species, the alumina cream technique has had limited success when applied
to animals other than the cat and rhesus monkey. Attempts to produce foci in the cebus
monkey, rabbit, and rat have had very limited success.
Alumina cream can be criticized as crude [45], since it creates lesions which are
quite large and difficult to reproduce precisely [21,35-40], averaging on the order of9
mm in diameter in some instances [49,50]. It is also a matter ofdispute as to whether
the alumina may diffuse away from its site of application. While some investigators
have maintained that the lesion stabilizes quickly and that diffusion is limited [40],
others have noted the "frequent diffusion of the active substance" [48], its spread to
adjacent regions ofcortex [32,35], or a progressive increase in thesizeofthe lesion over
time [37].
Another drawback ofthe alumina technique is thelong and somewhat unpredictable
latency period prior to the clinical and electrographic onset of spontaneous seizures.
Table 1 shows that delays offour toeight weeks are not uncommon in cats, whiledelays
ofsix to twelve weeks are fairly common in rhesus monkeys. Furthermore, a number of
authors have noted that results are frequently inconsistent [45]. For example, Stercova
was unable to produce an epileptogenic focus in the rat cortex [37] despite the success
of others [34]. In addition, individual animals may react to alumina quite differently
[14,32,30].
Table 1 also shows that the majority of studies using alumina cream have been
restricted to the sensorimotor cortex. It has been observed that other regions of the
telencephalon are less susceptible to alumina cream [14,19,20]. For example, Soper et
al. [44] found that large amounts of bilaterally administered alumina cream are
needed to produce temporal lobe seizures in monkeys. Other investigators have also
noted the need for bilateral administration ofalumina when dealing with areas outside
of the sensorimotor cortex [22,30,33]. It is questionable whether a model which
requires large bilateral lesions is a good representation ofthe human disease process.
In summary, while the alumina cream model may have been the first experimental
model developed to produce chronic epileptogenic foci, a number of factors limit its
applicability. For this reason, the alumina model has become less favored relative to
other, more recently developed techniques such as kindling and kainic acid.
THE KAINIC ACID MODEL
In 1970, Shinozaki and Konishi showed that kainic acid (KA), an analog of the
neuro-excitatory amino acid glutamate, had a potent excitatory effect upon rat cortical
neurons [15]. In the late 1970s and early 1980s, investigators became aware of the
potential use of kainic acid in experimental models of focal epilepsy. Hence, kainic
acid was applied to a variety of cortical and subcortical regions in various mammals.
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TABLE 1
Major Alumina Model Studies, 1942-1985
No. of Latency to Size of
Study Brain Site Species Animals First Seizure Lesion
Kopeloff et al.,
1942 [14]
Kopeloff et al.,
1942 [14]
Precentral cere-
bral cortex
Motor cortex
Barrera et al., Precentral cere-
1944 [21] bral cortex
Sloan et al.,
1953 [22]
Chusid et al.,
1953 [23]
Kopeloff et al.,
1954 [24]
Faeth et al.,
1955 [25]
Kopeloff et al.,
1955 [26]
Youmans,
1956 [27]
Amygdala-uni-
lateral and bi-
lateral
Eight sites in the
sensorimotor
Monkey
Rabbit
Rhesus monkey
Monkey
Rhesus monkey
cortex
Sensorimotor cor- Rhesus monkey
tex
Motor cortex Rhesus monkey
Sensorimotor cor- Rhesus monkey
tex, primarily.
Some parietal
cortex as well.
Temporal lobe Rhesus monkey
Morrell et al., Primary sensory Rhesus monkey
1956 [28] cortex and
amygdaloid-
hippocampal
region
Faeth and Thalamus, amyg- Rhesus monkey,
Walker, dala, putamen, cebus monkey
1957 [29] globus pallidus,
pons, nucleus
basalis-bilat-
eral
Gastaut et al., Amygdala, hippo- Cat
1958 [30] campus, pyri-
form cortex-
unilateral and
bilateral
Servit and Sterc,
1958 [31]
Motor and acous- Rat
tic area-uni-
lateral and bi-
lateral
26 4.5-6 weeks in 18
animals
8 Three and seven
weeks in two
animals. No
seizures in six
animals.
Post-operatively
to eight weeks.
No seizures in
some.
Eight weeks
(EEG abnor-
malities)
7 Three to four
weeks
4 4.5, 7, 9 weeks
24 6-12 weeks
196 >2.5 weeks in
182 animals
5 One day, one
week, seven
weeks +. No
seizures
9 16-24 weeks
16 No seizures
14 Three to five
weeks in 12 an-
imals. 24
weeks in one
animal. One
day in one ani-
mal.
75 2 days-1I weeks
in 25 animalsLOUIS ET AL.
Study
Gastaut et al.,
1959 [32]
Stamm and
Pribram,
1961 [33]
Sterc,
1962 [34]
Westrum et al.,
1964 [35]
Mayman et al.,
1965 [36]
Stercova,
1966 [37]
Velasco et al.,
1973 [38]
Velasco et al.,
1973 [39]
Harris,
1973 [40]
Mayanagi and
Walker,
1974 [41]
Mayanagi,
1976 [42]
Lockard et al.,
1976 [43]
Soper et al.,
1978 [44]
Mayanagi,
1979 [45]
Feria-Velasco et
al.,
1980 [46]
Harris and
Lockard,
1981 [47]
Beaumanoir et
al.,
1982 [48]
TABLE 1-continued
No. of Latency to Size of
Brain Site Species Animals First Seizure Lesion
Amygdala, hippo- Cat
campus, pyri-
form cortex,
adjacent to the
thalamostriatal
region
Inferotemporal Rhesus monkey
cortex-bilat-
eral
Acoustic and mo- Rat
tor cortex
Sensorimotor cor- Rhesus monkey
tex
Sensorimotor cor- Cat
tex
Motor and acous- Rat
tic cortex
Sensorimotor cor- Cat
tex
Sensorimotor cor- Cat
tex
Cortex Rhesus monkey
Temporal neocor- Rhesus monkey
tex
Temporal cortex, Rhesus monkey
amygdala, hip-
pocampus
Sensorimotor cor- Rhesus monkey
tex
Hippocampus- Monkey
unilateral and
bilateral
Lateral neocortex Rhesus monkey
or deep struc-
tures ofthe
temporal lobe
Motor cortex Cat
Sensorimotor cor- Rhesus monkey
tex
Peri-amygdaloid Cat
region
14 Four, five, one,
one, six, six,
five weeks in
seven animals.
One day in one
animal. No sei-
zures in six.
12 8-14 weeks
(EEG abnor-
malities)
4.5 weeks-au-
diogenic sei-
zures
8 Four to six weeks 2-3 mm in diam-
eter
16 Three weeks in Large (see Fig.
one animal. 1)
Six to eight
weeks in 15 an-
imals.
No seizures ob- Large (see Fig.
served 1)
18 5.5 weeks -1.0-2.5 mm in
diameter
16 4.5-6 weeks 3.2-4.3 mm in di-
ameter
32 Eight to ten
weeks
12 x = 8 weeks
12 6-12 weeks Large (see Figs.
1,2)
13 6-11 weeks
16 Three to ten
weeks
12 -8 weeks
24 Five to six weeks
15 8-12 weeks
Three to six
weeks
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TABLE 1-continued
No. of Latency to Size of
Study Brain Site Species Animals First Seizure Lesion
Velasco et al., Motor cortex Cat 63 4.5-5 weeks 5.3 ± 1.0 mm-
1984 [49] 9.3 ± 1.1 mm
in diameter
Velasco et al., Motor cortex Cat 8 4.5-5 weeks 5.3 ± 1.0 mm-
1985 [50] 9.3 ± 1.1 mm
in diameter
Table 2 provides a representative list of studies in which kainic acid has been applied
to a variety of structures including the amygdala [51-57], hippocampus [58-67],
striatum [68-72], and substantia nigra [69]. In addition, KA has been administered
subcutaneously [73-75], intravenously [76-80], and intraventricularly [56,70,81].
Its primary site of action seems to be the CA3 cells of the hippocampus
[53,59,61,64,65,70,71,73,77,79,81-85]. While few primary epileptogenic foci have
been successfully created outside of the temporal lobe and/or limbic regions, the KA
model has emerged as a model for temporal lobe epilepsy [59,61,65,77-79,82], since
the resulting clinical signs [69] and pathology [64,72,82] are similar to those seen in
patients with temporal lobe disease.
An important drawback of this model is the common but somewhat disputed
observation that the effects ofKA are not restricted to the site or anatomical structure
into which the KA is injected [50-53,55-57,62,64,68,70,72-75,81]. For instance,
Zaczek showed that intrastriatal applications of3H-labeled KA resulted in the spread
of KA to the following distant sites: ipsilateral frontal cortex, ipsilateral olfactory
cortex, ipsilateral lateral cortex, ipsilateral hippocampus, ipsilateral diencephalon,
ipsilateral medulla, ipsilateral pons, contralateral striatum, and contralateral olfactory
cortex [71]. Even iontophoretic application has had variable success in eliminating
distant damage [63,68]. On the other hand, Scherer-Singler and McGeer reported
little diffusion of 3H-labeled KA away from injection sites in the substantial nigra,
cerebellum, and neostriatum [86]. While some authors have implicated the direct
diffusion of KA [65], it appears that diffusion alone cannot explain the inhomogeneous
distribution of distant/secondary lesions [55,82], so that some form of neuronal
transport is likely to be involved. It has also been suggested that the lesion at the site of
injection may be the result of KA's toxicity, whereas distant lesions may be related to
the epileptogenic effects of the drug [50,51,55,62,80,83,86], since pretreatment with
anticonvulsants appears to limit distant damage [83].
While KA has been applied to the brains of a number ofdifferent species including
the baboon [55,57], rabbit [60], cat [58,62], and mouse [75], the large majority of
studies have been conducted in the rat (i.e., 29 of 35 studies listed in Table 2). The
majority of studies have considered the acute epileptogenic effects of KA administra-
tion [52,53,61,66,67,72,74,75,80,82,87]. It appears, however, that KA administration
may also result (after a variable silent period following the acute stage) in spontaneous
recurrent seizures ofa chronic nature [62,65].
To summarize, when KA is applied to the brains of various animals, it produces
predominantly limbic seizures which appear within a matterofminutes [52,53,55] and
remit after hours or days, but which may reappear spontaneously after a silent period
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TABLE 2
Major Kainate Model Studies, 1979-1984
Region or
Method of
KA Latency to
Study Administration Species First Seizure
Ben-Ari et Amygdala
al.,
1979 [53]
Menini et al., Amygdala
1979 [55]
Ben-Ari et Amygdala
al.,
1980 [56]
Ben-Ari et Amygdala
al.,
1980 [52]
Olney et al., Amygdala
1981 [54]
Cepeda et al., Amygdala
1982 [57]
Tremblay et Amygdala
al.,
1983 [51]
Zaczek et al., Hippocampus
1978 [67]
Rat 12 minutes
Baboon Four to eight
minutes
Last
Observed
Seizure
Several hours
15-150 hours
Rat
Rat 5-60 minutes Two to six
hours
Rat
Baboon 48-72 hours
Rat
Rat
Comments
Focal seizures
followed by
generalized
seizures
Locations of
Distant
Lesions
Ipsilateral
hippocam-
pus
Ipsilateral
hippocam-
pus and
neocortical
regions
Lateral sep-
tum, claus-
trum, con-
tralateral
cortical re-
gions, ipsi-
lateral hip-
pocampus
Hippocampus,
contralat-
eral amyg-
dala, bilat-
erally in
midline
thalamic
nuclei, con-
tralateral
claustrum,
cortical re-
gions, lat-
eral septum
Limbic sei- Piriform and
zures entorhinal
and tempo-
parietal
cortices,
hippocam-
pus, thala-
mus, lateral
septum
Status epilep- Bilateral hip-
ticus pocampus,
cortical re-
gions, thal-
amus
Two to six Tonic-clonic
hours seizures
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TABLE 2-continued
Region or
Method of Last Locations of
KA Latency to Observed Distant
Study Administration Species First Seizure Seizure Comments Lesions
Schwarcz et Hippocampus Rat 12 hours
al.,
1978 [61]
Kohler et al.,
1978 [64]
Nelson et al.,
1980 [66]
Munoz and
Grossman,
1980 [63]
Tanaka et al.,
1981 [58]
Smialowski
and
Smialowska,
1981 [60]
French et al.,
1982 [59]
Cavalheiro et
al.,
1982 [65]
Tanaka et al.,
1982 [62]
Tanaka et al.,
1982 [62]
Hippocampus Rat
Hippocampus Rat
Hippocampus Rat
Hippocampus Cat
Hippocampus Rabbit
Hippocampus Rat
Hippocampus Rat
Hippocampus Cat
Hippocampus Cat
Schwarcz and Striatum
Coyle,
1977 [69]
Schwob et al., Striatum
1980 [70]
Zaczek et al., Striatum
1980 [71]
Pisa et al., Striatum
1980 [72]
Overlying
cortex, thal-
amus,
amygdala,
piriform
cortex
30-50 minutes
lontophoretic No damage at
application distant sites
Status epilep-
ticus. Sec-
ondary
amygdaloid
focus
Prolonged
convulsions
Frozen ap-
pearance
during sei-
zures
Three to five 48-72 hours; Silent period
hours 22-46 days fromday 2
or 3 until
day 21
17-45 minutes Two to four Small doses
days
Approximately Approximately Large doses
10.8 days 21.6 days
Rat Six to eight Three to five Silent period
hours days ondays 1
and 2
Rat
Rat
Rat Immediate Four to five Clonicjerking
days
Both amyg-
dalas
Both amyg-
dalas and
piriform
cortex
Cortex overly-
ing stria-
tum
Piriform cor-
tex, hippo-
campus,
frontal cor-
tex
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TABLE 2-continued
Region or
Method of
KA Latency to
Study Administration Species First Seizure
Pisa et al., Striatum Rat
1980 [72]
Ruth,
1982 [68]
Striatum Rat
Last
Observed
Seizure
35-77 days
Comments
Generalized
seizures
lontophoreti-
cally ap-
plied
Schwob et al., Intracerebral Rat
1980 [70]
Schwarcz and Substantia ni- Rat
Coyle, gra
1977 [69]
Schwob et al., Intravenously Rat
1980 [70]
Lothman and Intravenously Rat
Collins,
1981 [80]
Lothman et Intravenously Rat
al.,
1981 [77]
Tremblay et Intravenously Rat
al.,
1984 [78]
Nitecka et al., Intravenously Rat
1984 [79]
Olney et al., Subcuta- Mice
1974 [75] neously
Olney et al., Subcuta-
1979 [73] neously
Sperk et al., Subcuta-
1983 [74] neously
Immediate Five days
30-90 minutes
One to two Limbic sei-
hours zures
Limbic sei-
zures
Limbic sei-
zures
15 minutes Two to three
hours
Rat
Rat Five minutes, Five hours
15-30 min-
utes, two
hours
Staring. Myo-
clonic
twitching.
Tonic-
clonic sei-
zures
Locations of
Distant
Lesions
Piriform cor-
tex, hippo-
campus,
frontal cor-
tex
Hippocampi
are not
damaged.
Damage
found in
substantia
nigra, ven-
tral thala-
mus, pars
reticulata.
Widespread
distant
damage
Olfactory
cortex,
amygdala,
thalamus,
hippocam-
pus, neocor-
tical regions
Arcuate nu-
cleus and
hypothala-
mus
Hippocampus
Amygdala,
piriform
and ento-
rhinal cor-
tices, olfac-
tory areas
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TABLE 2-continued
Region or
Method of Last Locations of
KA Latency to Observed Distant
Study Administration Species First Seizure Seizure Comments Lesions
Nadler et al., Intravenously Rat Hippocampus
1978 [81]
Ben-Ari et Intravenously Rat Seizures Pyriform cor-
al., tex, claus-
1980 [56] trum, hip-
pocampus,
contralat-
eral cortex
[62,65]. The pathological, clinical, and electrographic characteristics of the resulting
seizure syndrome strongly resemble those seen in human temporal lobe epilepsy.
However, the production ofnumerous lesions outsideofthe injection site, as well as the
overly high susceptibility oftemporal lobe structures, limit the use ofthe KA model.
THE ELECTRICAL KINDLING MODEL
In 1961, Delgado and Sevillano observed that repeated electrical stimulation of the
cat hippocampus resulted in seizure activity [88]. In 1967 [16] and again in 1969 [89],
Goddard et al. reported that the repeated administration of low levels of electrical
current to subcortical regions in rats, cats, and rhesus monkeys resulted in localized
seizure discharges, automatisms, and, eventually, clonic convulsions. He coined the
term "kindling" to refer to the aforementioned phenomenon [89]. "Kindling" may be
defined as "the phenomenon whereby repeated administration of an initially subcon-
vulsive electrical or chemical stimulus results in progressive intensification of seizure
activity, culminating in a generalized seizure" [88]. In the past several decades, a
multitude ofpapers have been published on thekindling technique, as it is probably the
most widely employed experimental model ofchronic focal epilepsy in use today. Table
3 provides the reader with a representative list ofelectrical kindling technique studies
conducted in the past twenty-five years [16,89-107]. Some of the advantages of this
technique are as follows. The kindling technique may be employed on a wide variety of
species, including frog [97,98], lizard [102,103], rat [90,91,105], mouse [96], rabbit
[92], dog [101,104], cat [93,100], rhesus monkey [89], and baboon [94,99]. In
addition, kindling does not produce destructive pathologies such as those associated
with most other experimental models [108]. Rather, it has been suggested that
kindling may be associated only with the structural modification of pre-existing
synapses [109]. Finally, the kindling technique is applicable to numerous cortical
regions [109].
Despite the advantages offered by the kindling technique, there are a number of
problems associated with it. First, there seems to be a hierarchy ofsensitivity in various
brain sites to the kindling technique. The amygdala and globus pallidus appear to be
the most sensitive structures, while the hippocampus appears to be relatively less
sensitive [89,95]. It may require as long as 8.5 weeks ofdaily electrical stimulation to
kindle seizures in the rat hippocampus [95], 13 weeks to kindle seizures in the cat
prefrontal cortex [100], 21 weeks to kindle seizures in the baboon mesial frontal cortex
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TABLE 3
Representative Electrical Kindling Studies, 1967-1985
Region of
Study Brain
Goddard, Amygdala, R
1967 [16] septal area
caudate, pu-
tamen, globus
pallidus
Goddard et al., Subcortical R
1969 [89] structures,
dorsal cortex,
entorhinal
cortex, olfac-
tory bulb
% of
Time Animals
Species Number Elapsed Which
of of Prior to Progressed Were
Experi- Experi- First Through All Seizures
mental mental Tonic-Clonic Stages of Spon-
Animal Animals Seizure Kindling taneous?
at 77 4-136 days 58 No
'at 294 22-77 days
Cat Several
Amygdala Rhesus Six
monkey
Racine, Amygdala, hip- Rat 140
1972 [90] pocampus,
mesencepha-
lon, reticular
formation
Racine, Amygdala, hip- Rat 56
1972 [91] pocampus
Tanaka, Amygdala Rabbit
1972 [92]
Wada et al., Amygdala Cat 21
1974 [93]
Wada et al., Amygdala Baboon Four
1975 [94]
Burnham, Amygdala, sep- Rat 80
1976 [95] tal region,
hippocampus
Leech and Amygdala-pir- Mice 37
McIntyre, iform area
1976 [96]
Morrell and Hippocampus Frog 60
Tsuru,
1976 [97]
Morrell et al., Hippocampus Frog 60
1976 [98]
Wada et al., Pre-frontal cor- Baboon Two
1976 [99] tex
Wake and Amygdala Cat 14
Wada,
1976 [100]
Cortical regions Cat
Wauquier et al., Amygdala, hip- Dog
1976 [101] pocampus
Eight
No
30-60 days
Six months
5-65 days
5-36 days
No
No
No
100 Sometimes
100 Yes
6-60 days No
Sometimes
Sometimes
318 days in
one animal
15-36 days
8-91 days
No
100 No
100 No
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TABLE 3-continued
% of
Time Animals
Species Number Elapsed Which
of of Prior to Progressed Were
Experi- Experi- First Through All Seizures
Region of mental mental Tonic-Clonic Stages of Spon-
Study Brain Animal Animals Seizure Kindling taneous?
Rial and Telencephalon Lizard
Gonzalez,
1977 [102]
Rial and Dorsal telence- Lizard 80 17 days No
Gonzalez, phalic cortex
1978 [103]
Wauquier et al., Amygdala Dog Eight 2-14 days 100 Sometimes
1979 [104]
Le Gal La Salle, Amygdala Rat 83 15-45 days 97 No
1981 [105]
Araki et al., Amygdala, Rat No
1983 [106] frontal cortex,
reticular for-
mation, hip-
pocampus
Wada et al., Mesial frontal Monkey Six 62-147 50 Sometimes
1985 [107] cortex
Orbital cortex Monkey Three 0 No
[107], and 45.5 weeks to kindle seizures in the baboon prefrontal cortex [99]. It has
also been suggested that kindling becomes increasingly difficult in phylogenetically
more advanced experimental animals. It is unclear whether this is a problem inherent
in either ofthe aforementioned models.
Second, while the kindling technique may induce recurrent focal seizures, these
seizures are not consistently spontaneous. Often, they must be triggered by electrical
stimulation [99,107]. In addition, it is frequently observed that all animals placed
under identical experimental conditions do not fully progress through all five stages of
kindling. More important, numerous animals fail to develop any seizure activity
[16,107].
THE TETANUS TOXIN MODEL
Tetanus toxin is a potent neurotoxin-protein which is produced by the gram-positive
bacillus Clostridium tetani [110]. After binding to the gangliosides GDlb and GTlb
[ 1 1], the toxin is transported up axons in a retrograde fashion [1 12] until it reaches
the synapses, where it seems to act by blocking the presynaptic release of inhibitory
neurotransmitters, especially GABA and glycine [112,113].
Tetanus toxin was first used to create chronic epileptiform events in 1962 [114],
when Carrea and Lanari applied it to the cerebral cortex of63 dogs. The toxin induced
epileptogenic foci which were present for up to two months [114]. Mellanby and
George write that "because ofits potency, its large molecular size and the fact that it is
rapidly bound to receptors, tetanus toxin would appear to be an ideal agent for
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TABLE 4
Major Tetanus Toxin Model Studies, 1962-Present
Species Number Time Elapsed
of of Prior to Last
Region of Experimental Experimental Onset of Observed Size of
Study Brain Animal Animals First Seizure Seizure Lesion
Carrea and La- Cerebral cortex Dog 63 Two to seven Two Small
nari, days, 34 ani- months
1962 [114] mals
Brooks and Motor cortex Cat Two to six hours
Asanuma,
1962 [115]
Glaser and Yu, Dorsal hippo- Cat Two hours 26 hours
1977 [116] campus
Mellanby et al., Hippocampus Rat >7 days Two Small
1977 [117] months
Mellanby and Hippocampus Rat Approximately Five
George, three days weeks
1979 [110]
McGeer et al., Substantia nigra Rat >8 Immediately Three to
1980 [118] and thalamus five
days
(death)
McGeer et al., Caudate Rat >4 Three to five Ten days
1980 [118] days (death)
McGeer et al., Hippocampus Rat None observed
1980 [118]
Darcey and Hippocampus Cat Eight Two to five
Williamson, weeks
1985 [121]
producing highly localized 'pharmacological lesions' after local injection into specified
brain regions" [110]. Table 4 provides the reader with a list of the major studies
involving the direct application of tetanus to the brain. Several points should be
emphasized. First, despite the fact that tetanus toxin was first used 25 years ago to
create epileptogenic foci in laboratory animals, the tetanus toxin model is still very
much in its developmental stages and is utilized in few laboratories. Second, after the
local application of tetanus toxin to the brains ofexperimental animals, there seems to
be a relatively short latency period prior to the clinical and electrographic onset of
chronic seizures. This latency period varies from several hours to several weeks
[110,1 14-118]. Recently, we have observed the onset of spontaneous and recurrent
focal seizures in the cat hippocampus, orbital frontal cortex, and motor cortex within
two to three weeks. In addition, tetanus toxin induces seizure foci which may remain
chronically active. Mellanby et al. have induced foci in the rat hippocampus which
remain active for up to two months [117]. Epileptogenic foci in the cat hippocampus
may remain active indefinitely [1 19].
Tetanus toxin appears to produce a relatively small lesion [117]. Our own
observations of the lesions produced in the cat hippocampus confirm that the lesions
are relatively small areas of necrosis and reactive gliosis. In addition, the lesions are
well confined [117]. A study by Mellanby et al. using small amounts of radioactively
labeled tetanus toxin indicated that the toxin remains confined to the site of injection
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TABLE 5
A Comparison of Four Experimental Models of Chronic Epilepsy
Characteristic of Tetanus
Particular Model Alumina Model Kainate Model Kindling Model Toxin Model
Short latency period prior to onset of No Yes No Yes
first seizure
Creates a small lesion No No Yes Yes
Creates a confined lesion Yes No Yes Yes
Applicable to numerous telence- Yes Yes Yes Yes
phalic regions
Equally applicable to different re- No No No Yes
gions
Produces a chronic focus Yes Yes Yes Yes
May be employed on a wide variety No No Yes Untested
ofspecies (Number ofspecies (3-4) (4) (9) (3)
which have successfully developed
epileptogenic foci)
Seizures are always spontaneous Yes Yes No Yes
Entries in italics imply that the particular characteristic which is not present is important.
(i.e., the hippocampus) [120]. Our own observations of H and E and cresyl violet
stained cat hippocampi confirm that the lesion is well confined.
In addition, tetanus toxin is applicable to numerous telencephalic regions, as
evidenced by its successful application to the hippocampus [110,116,117,121], sub-
stantia nigra [118], thalamus [118], caudate [118], orbital frontal cortex [119],
cerebral cortex (region unspecified) [114], and motor cortex [115]. It also seems that
many ofthe aforementioned regions are equally sensitive to theeffects oftetanus toxin.
For example, we have observed that similar doses of tetanus toxin are required to
induce epileptogenic foci in the cat hippocampus, orbital frontal cortex, and motor
cortex.
It should be emphasized that the amount of experience with tetanus toxin is
relatively limited compared to the other models and that additional work must be
conducted in order to better define the model. For example, the toxin has not been
applied to very many species. In addition, the optimal schedule oftoxin adminsitration
has not been established, and the histopathological changes are not well documented.
Despite these drawbacks, it is apparent that when tetanus toxin is applied to different
regions ofthe brain in various experimental animals, it induces a chronic epileptogenic
focus in a relatively short time. These features make it an attractive and potentially
superior experimental model offocal epilepsy.
DISCUSSION
We have reviewed four chronic experimental models of focal epilepsy. Table 5
combines much of the data in a more compact form. We would like to emphasize a
number of points. First, it is quite apparent that both the alumina model and the
kainate model are associated with drawbacks (see italicized entries in Table 5). With
alumina gel, the precise extent ofthe lesion is difficult to control, which is problematic
for studies requiring a very discrete anatomical focus. Kainate may create numerous
secondary lesions in spite ofgreat care in its initial application.
The kindling model is associated with fewer flaws than either the alumina or kainate
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models. Probably for this reason, the kindling model is more widely used than either of
these two models. Kindling does not always result in spontaneous seizures, however,
and all regions ofthe brain are not equally susceptible to this technique.
In so far as it has been studied to date, the tetanus toxin model compares quite
favorably with the kindling model and possesses a number of positive features which
are not present in the kindling model, such as the short latency prior to onset of
seizures, the consistent spontaneity ofseizures, and the comparable applicability ofthe
toxin todifferent telencephalic regions. In short, the tetanus toxin model seems to be an
excellent model for the rapid and relatively non-destructive creation of spontaneous
recurrent seizures in numerous pre-selected foci ofthe mammalian brain.
REFERENCES
1. Hauser WA, Kurland LT: The epidemiology ofepilepsy in Rochester, Minnesota, 1935 through 1967.
Epilepsia 16:1-66, 1975
2. Rayport M: Role of neurosurgery in the management of medication-refractory epilepsy. Commission
for the Control of Epilepsy and Its Consequences, Plan for Nationwide Action on Epilepsy. DHEW
Publication No. (NIH):314-343, 1978
3. Soloway S, Williamson PD, Spencer D, et al: Surgery for epilepsy: role ofdepth electroencephalogra-
phy. Conn Med 44:70-75, 1980
4. Kopeloff LM: Experimental epilepsy in the mouse. Proceedings of the Society for Experimental
Biology and Medicine 104:500-504, 1960
5. Mutani R: Cobalt experimental amygdaloid epilepsy in the cat. Epilepsia 8:73-92, 1967
6. Mutani R: Cobalt experimental hippocampal epilepsy. Epilepsia 8:223-240, 1967
7. Blum B, Liban E: Experimental baso-temporal epilepsy in the cat. Discrete epileptogenic lesions
produced in the hippocampus or amygdaloid by tungstic acid. Neurology 10:546-554, 1960
8. Blum B, Magnes J, Bental E, et al: Electroencephalographic studies in cats with experimentally
produced hippocampal epilepsy. Electroenceph clin Neurophysiol 13:340-353, 1961
9. Papavasiliou PS, Kutt H, Miller S, et al: Seizure disorders and trace metals: manganese tissue levels in
treated epileptics. Neurology 29:1466-1473, 1979
10. Pei Y, Zhao D, Huang T, et al: Zinc-induced seizures: a new experimental model ofepilepsy. Epilepsia
24:169-176, 1983
11. Morrell F, Bradley W, Ptashne M: Effects of drugs on discharge characteristics of chronic
epileptogenic lesions. Neurology 9:492-498, 1959
12. Remler M, Marcussen W: Chronicepileptogenesis in rats by systemic convulsant and focal blood brain
barrier lesion method. Epilepsia 25:670-671, 1984
13. Remler M, Marcussen W: Systemic focal epileptogenesis. Epilepsia 27:35-42, 1986
14. Kopeloff LM, Barrera SE, Kopeloff N: Recurrent convulsive seizures in animals produced by
immunologic and chemical means. Am J Psych 98:881-902, 1942
15. Shinozaki H, Konishi S: Actions of several anthelmintics and insecticides on rat cortical neurones.
Brain Res 24:368-371, 1970
16. Goddard G: Development of epileptic seizures through brain stimulation at low intensity. Nature
214:1020-1021, 1967
17. Purpura DP, Penry JK, Tower D, Woodbury DM, Walter R: Experimental Models of Epilepsy. New
York, Raven Press, 1972
18. Kopeloff N, Whittier JR, Pacella BL, et al: The epileptogenic effect of subcortical alumina cream in
the rhesus monkey. Electroenceph clin Neurophysiol 2:163-168, 1950
19. Kopeloff LM, Chusid JG, Kopeloff N: Chronic experimental epilepsy in macaca mulatta. Neurology
4:218-227, 1954
20. Ward AA: Topical convulsant metals. In Experimental Models ofEpilepsy. Edited by DPPurpura, JK
Penry, D Tower, DM Woodbury, R Walter. New York, Raven Press, 1972
21. Barrera SE, Kopeloff LM, Kopeloff N: Brain lesions associated with experimental "epileptiform"
seizures in the monkey. Am J Psych 100:727-737, 1944
22. Sloan N, Ransohoff J, Pool JL: Clinical and EEG seizures following chronic irritative lesions of the
medial temporal region in monkeys. Electroenceph clin Neurophysiol 5:320-321, 1953EPILEPSY MODEL-TETANUS TOXIN 269
23. Chusid JG, Kopeloff LM, Kopeloff N: Experimental chronic epilepsy in the monkey following
intracerebral injections ofaluminum hydroxide cream. Electroenceph clin Neurophysiol 5:321, 1953
24. Kopeloff N, Chusid JG, Kopeloff LM: Epilepsy produced in macaca mulatta with commercial
aluminum hydroxide. Electroenceph clin Neurophysiol 6:303-306, 1954
25. Faeth WH, Walker AE, Kaplan AD, et al: Threshold studies on production of experimental epilepsy
with alumina cream. Proceedings of the Society of Experimental Biology and Medicine 88:329-331,
1955
26. Kopeloff LM, Chusid JG, Kopeloff N: Epilepsy in macaca mulatta after cortical or intracerebral
alumina. AMA Arch Neurol Psych 74:523-526, 1955
27. Youmans JR: Experimental production ofseizures in the macaque by temporal lobe lesions. Neurology
6:179-186, 1956
28. Morrell F, Roberts L, Jasper HH: Effect of focal epileptogenic lesions and their ablation upon
conditioned electrical responses of the brain in the monkey. Electroenceph clin Neurophysiol
8:217-236, 1956
29. Faeth WH, Walker AE: Studies on effect ofthe injection ofalumina (aluminum oxide) cream into the
basal ganglia. AMA Arch Neurol Psych 78:562-567, 1957
30. Gastaut H, Naquet R, Meyer A, et al: Clinical, electroencephalographic and anatomo-pathological
study of "psychomotor" epilepsy induced in the cat by injection ofalumina cream. In Temporal Lobe
Epilepsy. Edited by M Baldin, P Bailey. Springfield, IL, Charles Thomas Publisher, 1958, pp
240-242
31. Servit ZD, Sterc J: Audiogenic epileptic seizures evoked in rats by artificial epileptogenic foci. Nature
181:1475-1476, 1958
32. Gastaut H, Naquet R, Meyer A, et al: Experimental psychomotor epilepsy in the cat. Electro-clinical
and anato-pathological correlations. J Neuropath Exp Neurol 18:270-293, 1959
33. Stamm JS, Pribram KH: Effects of epileptogenic lesions of inferotemporal cortex on learning and
retention in monkeys. J Comp Physiol Psych 6:614-618, 1961
34. Sterc J: Experimental reflex epilepsy (audiogenic epilepsy). Epilepsia 3:252-273, 1962
35. Westrum LE, White LE, Ward AA: Morphology of the experimental epileptic focus. J Neurosurg
21:1033-1046, 1964
36. Mayman CI, Manlapaz JS, Ballantine HT, et al: A neuropathological study of experimental
epileptogenic lesions in the cat. J Neuropath Exp Neurol 24:502-511, 1965
37. Stercova A: Dynamics of neurohistopathological changes in an epileptogenic focus produced by
alumina cream in the rat. In Comparative and Cellular Pathophysiology in Epilepsy. Edited by Z
Servit. Amsterdam, Excerpta Medica Foundation, 1966, pp 247-257
38. Velasco M, Velasco F, Lozoya A, et al: Alumina cream-induced focal motor epilepsy in cats. Part 2.
Thickness and cellularity of cerebral cortex adjacent to epileptogenic lesions. Epilepsia 14:15-27,
1973
39. Velasco M, Velasco F, Estrada-Villaneuva F, et al: Alumina cream-induced focal motor epilepsy in
cats. Part 1. Lesion size and temporal course. Epilepsia 14:3-14, 1973
40. Harris AB: Ultrastructure and histochemistry ofalumina in the cortex. Exp Neurol 38:33-63, 1973
41. Mayanagi Y, Walker AE: Experimental temporal lobe epilepsy. Brain 97:423-446, 1974
42. Mayanagi Y: Experimental studies on the pathogenesis of temporal lobe epilepsy. Fol Psych Neurol
Jap 30:415-424, 1976
43. Lockard J, Congdon WC, DuCharme L, et al: Prophylaxis with diphenylhydantoin and phenobarbital
in alumina-gel monkey model. 1. Twelve months of treatment: seizure, EEG, blood and behavioral
data. Epilepsia 17:37-47, 1976
44. Soper HV, Strain GM, Babb TL, et al: Chronic alumina temporal lobe seizures in monkeys. Exp
Neurol 62:99-121, 1978
45. Mayanagi Y: Alumina cream-induced temporal lobeepilepsy in the monkey as an experimental model.
Fol Psych Neurol Jap 33:457-462, 1979
46. Feria-Velasco A, Olivares N, Rivas F, et al: Alumina cream-induced focal motor epilepsy in cats. IV.
Thickness and cellularity oflayers in the perilesional motor cortex. Arch Neurol 37:287--290, 1980
47. Harris AB, Lockard JS: Absence of seizures or mirror foci in experimental epilepsy after excision of
alumina astrogliotic scar. Epilepsia 22:107-122, 1981
48. Beaumanoir A, Naquet R, Vigouroux R: Temporal lobe epilepsy: experimental reproduction. In Henri
Gastaut and the Marseilles School's Contribution to the Neurosciences (EEG Suppl Number 35).
Edited by RJ Broughton. Amsterdam, Elsevier Biomedical Press, 1982, pp 159-170270 LOUIS ET AL.
49. Velasco M, Velasco F, Pacheco M, et al: Alumina cream-induced focal motor epilepsy in cats. Part 5.
Excision and transplant ofepileptogenic granuloma. Epilepsia 25:752-758, 1984
50. Velasco M, Velasco F, Marquez I, et al: Alumina cream induced focal motor epilepsy in cats. VI.
Excision ofthe perilesional cortex. Electroenceph clin Neurophysiol 60:548-557, 1985
51. Tremblay E, Ottersen OP, Rovira C, et al: Intra-amygdaloid injections of kainic acid: regional
metabolic changes and their relation to the pathological alterations. Neuroscience 8:299-315, 1983
52. Ben-Ari Y, Tremblay E, Ottersen OP: Injections ofkainic acid into theamygdaloid complex ofthe rat:
an electrographic, clinical and histological study in relation to the pathology ofepilepsy. Neuroscience
5:515-528, 1980
53. Ben-Ari Y, Lagowska J, Tremblay E, et al: A new model of focal status epilepticus: intra-amygdaloid
application of kainic acid elicits repetitive secondary generalized convulsive seizures. Brain Res
163:176-179, 1979
54. Olney JW, Fuller TA, de Gubareff T: Kainate-like neurotoxicity of folates. Nature 292:165-167,
1981
55. Menini C, Meldrum BS, Riche D, et al: Sustained limbic seizures induced by intraamygdaloid kainic
acid in the baboon: symptomatology and neuropathological consequences. Ann Neurol 8:501-509,
1980
56. Ben-Ari Y, Tremblay E, Ottersen OP, et al: The role ofepileptic activity in hippocampal and 'remote'
cerebral lesions induced by kainic acid. Brain Res 191:79-97, 1980
57. Cepeda C, Tanaka T, Riche D, et al: Limbic status epilepticus: behavior and sleep alterations after
intra-amygdaloid kainic acid microinjections in papio papio baboons. Electroenceph clin Neurophysiol
54:603-613, 1982
58. Tanaka T, Riche D, Kaijima M, et al: Experimental status epilepticus induced by a micro-injection of
kainic acid to the dorsal hippocampus in freely moving cats. Electroenceph clin Neurophysiol
52:S132-S133, 1981
59. French ED, Aldinio C, Schwarcz R: Intrahippocampal kainic acid, seizures and local neuronal
degeneration: relationships assessed in unanesthetized rats. Neuroscience 7:2525-2536, 1982
60. Smialowski A, Smialowska M: The effect of epileptiform discharges evoked by intrahippocampal
injeciton of kainic acid on cholinergic and catecholaminergic hippocampal afferents. Neuroscience
6:2510-2528, 1981
61. Schwarcz R, Zaczek-R, Coyle JT: Microinjection ofkainic acid into the rat hippocampus. European J
Pharmacol 50:209-220, 1978
62. Tanaka T, Kaijima M, Daita G, et al: Electroclinical features ofkainic acid-induced status epilepticus
in freely moving cats. Microinjection into the dorsal hippocampus. Electroenceph clin Neurophysiol
54:288-300, 1982
63. Munoz C, Grossman S: Some behavioral effects of selective neuronal depletion by kainic acid in the
dorsal hippocampus of rats. Physiology and Behavior 25:581-587, 1980
64. Kohler C, Schwarcz R, Fuxe K: Perforant path transactions project hippocampal cells from kainate
lesion. Neuroscience Letters 10:241-246, 1978
65. Cavalheiro EA, Riche DA, Le Gal La Salle G: Long-term effects of intrahippocampal kainic acid
injection in rats: a method for inducing spontaneous recurrent seizures. Electroenceph clin Neuro-
physiol 53:581-589, 1982
66. Nelson MF, Zaczek R, CoyleJT: Effects ofsustained seizures produced by intrahippocampal injection
of kainic acid on noradrenergic neurons: evidence for local control of norepinephrine release. J
Pharmacol Exp Therapeutics 214:694-702, 1980
67. Zaczek R, Nelson MF, Coyle JT: Effects of anaesthetics and anticonvulsants on the action of kainic
acid in the rat hippocampus. European J Pharmacol 52:323-327, 1978
68. Ruth RE: Kainate (KA) iontophoresis and remote damage. Anatomical Record 202:164A, 1982
69. Schwarcz R, Coyle JT: Neurochemical sequelaeofkainate injections in corpus striatum and substantia
nigra ofthe rat. Life Sciences 20:431-436, 1977
70. Schwob JE, Fuller T, Price JL, et al: Widespread patterns of neuronal damage following systemic or
intracerebral injections ofkainic acid: a histological study. Neuroscience 5:991-1014, 1980
71. Zaczek R, Simonton S, Coyle JT: Local and distant neuronal degeneration following intrastriatal
injection ofkainic acid. J Neuropathol Exp Neurol 39:245-264, 1980
72. Pisa M, Sanberg PR, Corcoran ME, et al: Spontaneously recurrent seizures after intracerebral
injections of kainic acid in rat: a possible model of human temporal lobe epilepsy. Brain Res
200:482-487, 1980EPILEPSY MODEL-TETANUS TOXIN 271
73. Olney JW, Fuller T, De GubareffT: Acute dendrotoxic changes in the hippocampus ofkainate treated
rats. Brain Res 176:91-100, 1979
74. Sperk G, Lassmann H, Baran H, et al: Kainic acid induced seizures: Neurochemical and histopatho-
logical changes. Neuroscience 10:1301-1315, 1983
75. Olney JW, Rhee V, Lan Ho 0: Kainic acid: a powerful neurotoxic analogue of glutamate. Brain Res
77:507-512, 1974
76. Ben-Ari Y, Tremblay E, Riche D, et al: Electrographic, clinical and pathological alterations following
systemic administration of kainic acid, bicuculline or pentetrazole: metabolic mapping using the
deoxyglucose method with special reference to the pathology of epilepsy. Neuroscience 6:1361-1391,
1981
77. Lothman EW, Collins RC, Ferrendelli JA: Kainic acid-induced limbic seizures: electrophysiologic
studies. Neurology 31:806-812, 1981
78. Tremblay E, Nitecka L, Berger ML, et al: Maturation ofkainic acid seizure-brain damage syndrome
in the rat. I. Clinical electrographic and metabolic observations. Neuroscience 13:1051-1072, 1984
79. Nitrecka L, Tremblay E, Charton G, et al: Maturation ofkainic acid seizure-brain damage syndrome
in the rat. II. Histopathological sequelae. Neuroscience 13:1073-1094, 1984
80. Lothman EW,Cohlins RC: Kainic acidinduced limbic seizures: metabolic, behavioral, electroencepha-
lographic and neuro-pathological correlates. Brain Res 218:299-318, 1981
81. Nadler JV, Perry BW, Cotman CW: Intraventricular kainic acid preferentially destroys hippocampal
pyramidal cells. Nature 271:676-677, 1978 I
82. Nadler JV: Minireview: kainic acid as a tool for the study of temporal lobe epilepsy. Life Sciences
29:2031-2042, 1981
83. Ben-Ari Y, Tremblay E, Ottersen OP, et al: Evidence suggesting secondary epileptogenic lesions after
kainic acid: pretreatment with diazepam reduces distant but not local brain damage. Brain Res
165:362-365, 1979
84. Ben-Ari Y: Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to
human temporal lobe epilepsy. Neuroscience 14:375-403, 1985
85. Nadler JV, Shelton DL, Perry BW, et al: Regional distribution of <3H> kainic acid after
intraventricular injection. Life Sciences 26:133-138, 1980
86. Scherer-Singler U, McGeer EG: Distribution and persistence of kainic acid in brain. Life Sciences
24:1015-1022, 1979
87. Wuerthele SM, Lovell KL, Jones MZ, et al: A histological study of kainic acid-induced lesions in the
rat brain. Brain Res 149:489-497, 1978
88. Delgado JMR, Sevillano M: Evolution ofrepeated hippocampal seizures in the cat. Electroenceph clin
Neurophysiol 13:722-733, 1961
89. Goddard GV, McIntyre DC, Leech CK: A permanent change in brain function resulting from daily
electrical stimulation. Exp Neurol 25:295-330, 1969
90. Racine RJ: Modification of seizure activity by electrical stimulation: I. After-discharge threshold.
Electroenceph clin Neurophysiol 32:269-279, 1972
91. Racine RJ: Modification ofseizure activity by electrical stimulation: II. Motor seizure. Electroenceph
clin Neurophysiol 32:281-294, 1972
92. Tanaka A: Progressive changes ofbehavioral and electroencephalographic responses to daily amygda-
loid stimulation in rabbits. Fukuoka Act Med 63:152-163, 1972
93. Wada JA, Sato M, Corcoran ME: Persistent seizure susceptibility and recurrent spontaneous seizures
in kindled cats. Epilepsia 15:465-478, 1974
94. Wada JA, Osawa T, Jung E: Spontaneous recurrent generalized seizure state induced by daily
amygdaloid stimulation in Sengalese baboon, papio papio. Electroenceph clin Neurophysiol 38:545,
1975
95. Burnham W: Primary and "transfer" seizure development in the kindled rat. In Kindling. Edited by
JA Wada. New York, Raven Press, 1976, pp 61-83
96. Leech CK, McIntyre DC: Kindling rates in inbred mice: an analog to learning? Behavioral Biology
16:439-452, 1976
97. Morrell F, Tsuru N: Kindling in the frog: development of spontaneous epileptiform activity.
Electroenceph clin Neurophysiol 40:1-11, 1976-
98. Morrell F, Tsuru N, Hoeppner TJ, Morgan D, Harrison WH: Secondary epileptogenesis in frog
forebrain: effect ofinhibition ofprotein synthesis. In Kindling. Edited by JA Wada. New York, Raven
Press, 1976, pp 41-60272 LOUIS ET AL.
99. Wada JA, Osawa T, Mizoguchi T: Recurrent spontaneous seizure state induced by prefrontal kindling
in sengalese baboons, papio papio. In Kindling. Edited by JA Wada. New York, Raven Press, 1976, pp
173-202
100. Wake A, Wada JA: Frontal cortical kindling in cats. In Kindling. Edited by JA Wada. New York,
Raven Press, 1976, pp 203-214
101. Wauquier A, Melis W, Desmedt LKC, Sadowski B: Self stimulation in dogs: behavioral effects of
anterior basal forebrain, amygdala and lateral hypothalamus implanatations. In Brain Stimulation
Record. Edited by A Wauquier, ET Rolls. Amsterdam, North-Holland, 1976, pp 427-430
102. Rial RV, Gonzalez J: The effect ofdiphenylhydantoin in the prevention ofthe threshold descents in the
electroshock on the reptilian telencephalon. In Post-traumatic Epilepsy. Edited by J Majkowski.
Warsaw, Polish Chapter ofthe ILAE, 1977, pp 203-208
103. Rial RV, Gonzalez J: Kindling effect in the reptilian brain: motor electrographic manifestations.
Epilepsia 19:581-589, 1978
104. Wauquier A, Ashton D, Melis W: Behavioral analysis ofamygdaloid kindling in beagle dogs and the
effects of clonazepam, phenobarbital, diphenylhydantoin, and flunarizine on seizure manifestation.
Exp Neurol 64:579-586, 1979
105. Le Gal La Salle G: Amygdaloid kindling in the rat: regional differences and general properties. In
Kindling 2. Edited by JA Wada. New York, Raven Press, 1981, pp 31-47
106. Araki H, Aihara H, Watanabe S, Ohta H, Yamamoto T, Veki S: The role of noradrenergic and
serotonergic systems in the hippocampal kindling effect. Jap J Pharmacol 33:57-64, 1983
107. Wada JA, Mizoguchi T, Komai S: Kindling epileptogenesis in orbital and mesial frontal cortical areas
ofsubhuman primates. Epilepsia 26:472-479, 1985
108. Wada JA, Osawa J, Mizoguchi T: Recurrent spontaneous seizure state induced by prefrontal kindling
in sengalese baboons, papio papio. In Kindling. Edited by JA Wada. New York, Raven Press, 1976, pp
173-202
109. McNamara JO, Byrne MC, Dasheiff RM, et al: The kindling model of epilepsy: a review. Progr
Neurobiol 15:139-159, 1980
110. Mellanby J, George G: Tetanus toxin and experimental epilepsy in rats. Adv Cytopharmacol
3:401-408, 1979
111. Svennerholm L: Chromatographic separation ofhuman brain gangliosides. J Neurochem 10:613-623,
1963
112. Van Heyningen S: Tetanus Toxin. Pharmac Ther 11:141-157, 1980
113. Curtis DR, Felix D, Game CJA, McGulloch RM: Tetanus toxin and the synaptic release of GABA.
Brain Res 51:358-362, 1973
114. Carrea R, Lanari A: Chronic effect of tetanus toxin applied locally to the cerebral cortex of the dog.
Science 137:342-343, 1962
115. Brooks VB, Asanuma H: Action oftetanus toxin in the cerebral cortex. Science 137:674-676, 1962
116. Glaser GH, Yu RK: A model of hippocampal epilepsy produced by tetanus toxin. Neurology 27:337,
1977
117. Mellanby J, George G, Robinson A, Thompson P: Epileptiform syndrome in rats produced by injecting
tetanus toxin into the hippocampus. J Neurol Neurosurg Psych 40:404-414, 1977
118. McGeer PL, McGeer EG, Campbell JJR: Rotaryeffects ofintra-cerebral tetanus toxin injections. Exp
Neurol 67:363-367, 1980
119. Darcey T, Williamson P: Personal communication
120. Mellanby J, Hawkins C, Mellanby H, Rawlins J, Impey ME: Tetanus toxin as a tool for studying
epilepsy. J Physiol (Paris) 79:207-215, 1984
121. Darcey TM, Williamson PD: Tetanus toxin model for focal epilepsy. In Proceedings of the XVIth
Epilepsy International Congress. New York, Raven Press, 1985